Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion.

IF 4 2区 医学 Q2 ONCOLOGY
Translational lung cancer research Pub Date : 2025-04-30 Epub Date: 2025-04-16 DOI:10.21037/tlcr-2024-1205
Wen Zhao, Jian-Xun Wen, Yan Niu, Li Yan, Mei-Ying Wang, Wei Jiao, Ya-Fei Wang, Wen-Hui Gao, Dan-Ni Yang, Wen-Qi Zheng, Zhi-De Hu
{"title":"Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion.","authors":"Wen Zhao, Jian-Xun Wen, Yan Niu, Li Yan, Mei-Ying Wang, Wei Jiao, Ya-Fei Wang, Wen-Hui Gao, Dan-Ni Yang, Wen-Qi Zheng, Zhi-De Hu","doi":"10.21037/tlcr-2024-1205","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Biomarkers in pleural fluid are the potential auxiliary diagnostic markers for malignant pleural effusion (MPE). Exosomal microRNAs (miRNAs) represent novel diagnostic markers for various diseases. The diagnostic performance of exosomal miRNAs for MPE remains unclear. Therefore, we examined the exosomal miRNAs profiles of both MPE and benign pleural effusion (BPE), aiming to study diagnostic performance of exosomal miRNAs for MPE.</p><p><strong>Methods: </strong>We used next-generation sequencing (NGS) technology to analyze the pleural fluid exosomal miRNA profile in five MPE and 15 BPE cases. We analyzed the differentially expressed exosomal miRNAs by reverse transcription polymerase chain reaction (RT-PCR), with cel-miR-39 or snRNA U6 as internal references. We assessed the diagnostic accuracy of exosomal miRNA for MPE with a receiver operating characteristic (ROC) curve. We also analyzed whether exosomal miRNA could improve the diagnostic performance of pleural carcinoembryonic antigen (CEA).</p><p><strong>Results: </strong>Fifty-eight miRNAs were up-regulated, and 35 miRNAs were down-regulated in MPE. We selected exosomal miR-182-5p for further study and analyzed miR-182-5p in 153 patients with undiagnosed pleural effusion. Exosomal miR-182-5p was undetectable in 32 participants. In the remaining participants with 49 MPE and 72 BPE cases, we found that the areas under the curve (AUCs) and their 95% confidence intervals (95% CIs) for exosomal miR-182-5p were 0.78 (95% CI: 0.69-0.86) when using cel-miR-39 as an internal reference, and 0.80 (95% CI: 0.73-0.88) when using snRNA U6. The combination of exosomal miR-182-5p and CEA can slightly improve the diagnostic accuracy of MPE, with an AUC of 0.91 (95% CI: 0.85-0.97).</p><p><strong>Conclusions: </strong>Pleural miR-182-5p can assist in the diagnosis of MPE. Its diagnostic performance is slightly affected by internal reference.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 4","pages":"1138-1148"},"PeriodicalIF":4.0000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082201/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-2024-1205","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Biomarkers in pleural fluid are the potential auxiliary diagnostic markers for malignant pleural effusion (MPE). Exosomal microRNAs (miRNAs) represent novel diagnostic markers for various diseases. The diagnostic performance of exosomal miRNAs for MPE remains unclear. Therefore, we examined the exosomal miRNAs profiles of both MPE and benign pleural effusion (BPE), aiming to study diagnostic performance of exosomal miRNAs for MPE.

Methods: We used next-generation sequencing (NGS) technology to analyze the pleural fluid exosomal miRNA profile in five MPE and 15 BPE cases. We analyzed the differentially expressed exosomal miRNAs by reverse transcription polymerase chain reaction (RT-PCR), with cel-miR-39 or snRNA U6 as internal references. We assessed the diagnostic accuracy of exosomal miRNA for MPE with a receiver operating characteristic (ROC) curve. We also analyzed whether exosomal miRNA could improve the diagnostic performance of pleural carcinoembryonic antigen (CEA).

Results: Fifty-eight miRNAs were up-regulated, and 35 miRNAs were down-regulated in MPE. We selected exosomal miR-182-5p for further study and analyzed miR-182-5p in 153 patients with undiagnosed pleural effusion. Exosomal miR-182-5p was undetectable in 32 participants. In the remaining participants with 49 MPE and 72 BPE cases, we found that the areas under the curve (AUCs) and their 95% confidence intervals (95% CIs) for exosomal miR-182-5p were 0.78 (95% CI: 0.69-0.86) when using cel-miR-39 as an internal reference, and 0.80 (95% CI: 0.73-0.88) when using snRNA U6. The combination of exosomal miR-182-5p and CEA can slightly improve the diagnostic accuracy of MPE, with an AUC of 0.91 (95% CI: 0.85-0.97).

Conclusions: Pleural miR-182-5p can assist in the diagnosis of MPE. Its diagnostic performance is slightly affected by internal reference.

外泌体miR-182-5p是恶性胸腔积液的潜在诊断标志物。
背景:胸腔液中的生物标志物是恶性胸腔积液(MPE)潜在的辅助诊断标志物。外泌体microRNAs (miRNAs)是多种疾病的新型诊断标志物。外泌体mirna对MPE的诊断性能尚不清楚。因此,我们检测了MPE和良性胸腔积液(BPE)的外泌体miRNAs谱,旨在研究外泌体miRNAs对MPE的诊断作用。方法:采用新一代测序(NGS)技术对5例MPE和15例BPE患者的胸膜液外泌体miRNA进行分析。我们用逆转录聚合酶链反应(RT-PCR)分析了差异表达的外泌体miRNAs,以cell - mir -39或snRNA U6为内参。我们用受试者工作特征(ROC)曲线评估外泌体miRNA对MPE的诊断准确性。我们还分析了外泌体miRNA是否可以提高胸膜癌胚抗原(CEA)的诊断效能。结果:MPE中有58个mirna上调,35个mirna下调。我们选择外泌体miR-182-5p进行进一步研究,并分析了153例未确诊胸腔积液患者的miR-182-5p。在32名参与者中检测不到外泌体miR-182-5p。在其余49例MPE和72例BPE的参与者中,我们发现外泌体miR-182-5p的曲线下面积(auc)及其95%置信区间(95% CI)当使用cel-miR-39作为内部参考时为0.78 (95% CI: 0.69-0.86),当使用snRNA U6时为0.80 (95% CI: 0.73-0.88)。外泌体miR-182-5p联合CEA可略微提高MPE的诊断准确率,AUC为0.91 (95% CI: 0.85-0.97)。结论:胸膜miR-182-5p可辅助MPE的诊断。其诊断性能受内部参考影响较小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
2.50%
发文量
137
期刊介绍: Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信